Business
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
First U.S. patient dosed at a mid-tier dose level where multiple responses have been observedMulti-regional trial to accelerate time to proof-of-concept data in 1H 2026 BELTSVILLE, Md. and SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, and Simcere Zaiming, an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), to
About this update from Simcere Pharmaceutical Group Limited
[{"type":"image","alt":"NextCure","displaySize":"","headline":null,"caption":"NextCure","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":52,"url":"https://media.zenfs.com/en/globenewswire.com/2b022401d79a308503f232df5a438de4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ekxc_WYboknOJJShVHRA9A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTczO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/2b022401d79a308503f232df5a438de4","width":300,"height":52}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First U.S. patient dosed at a mid-tier dose level where multiple responses have been observed","length":93,"tagName":"p"}]},{"val":[{"type":"text","content":"Multi-regional trial to accelerate time to proof-of-concept data in 1H 2026","length":75,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":168,"olType":false},{"type":"text","content":"BELTSVILLE, Md. and SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, and Simcere Zaiming, an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced that the first patient in the U.S. has been dosed with SIM0505 in the ongoing Phase 1 trial (NCT06792552), which is evaluating safety, tolerability, pharmacokinetics and efficacy in patients with advanced solid tumors.","length":563,"tagName":"p"},{"type":"text","content":"SIM0505 is a novel antibody drug conjugate directed to cadherin-6 (CDH6 ADC), featuring a proprietary topoisomerase 1 inhibitor (TOPOi) payload, designed for broad anti-tumor activity, high systemic clearance and an improved potential therapeutic window. NextCure has now expanded the ongoing Phase 1 dose escalation study, which was initiated in China, by enrolling patient(s) in the U.S. into a mid-tier dose level while dose escalation is currently advancing in China. NextCure acquired an exclusive global license, excluding Greater China, for SIM0505 from Simcere Zaiming.","length":577,"tagName":"p"},{"type":"text","content":"“We are pleased by the significant progress achieved by our partner, which has enabled us to start U.S. enrollment at doses within a therapeutic range where clinical responses have already been observed. Based on current data...